Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jul 3;30(7):1220-1222.
doi: 10.1093/ibd/izae078.

Ustekinumab Offers Long-Term Clinical Remission With Safety in Very Early-Onset Inflammatory Bowel Disease

Itaru Iwama  1 , Masashi Yoshida  1 , Ayako Miyazawa  1 , Tomoko Hara  1 , Ryusuke Nambu  1
Affiliations
Case Reports

Ustekinumab Offers Long-Term Clinical Remission With Safety in Very Early-Onset Inflammatory Bowel Disease

Itaru Iwama et al. Inflamm Bowel Dis. .
No abstract available

Keywords: steroid-free clinical remission; ustekinumab; very early-onset inflammatory bowel disease.

Plain language summary

We observed efficacy and safety of ustekinumab in very early-onset inflammatory bowel disease, which has not been previously reported. Clinical remission at 52% was 75%, often persisting beyond 2 years. Further studies including larger numbers of cases are needed to confirm this observation.

PubMed Disclaimer

Conflict of interest statement

I.I. and R.N. have received lecture fees from Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceutical K.K., AbbVie Inc, Mochida Pharmaceutical Co, Ltd, and Miyarisan Pharmaceutical Co, Ltd. The other authors disclose no conflicts.

Similar articles

See all similar articles

References

    1. Kelsen JR, Sullivan KE, Rabizadeh S, et al.North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the evaluation and management for patients with very early-onset inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2020;70(3):389-403. - PubMed
    1. Collen LV, Mitsialis V, Kim DY, et al.Efficacy and safety of anti-tumor necrosis factor alpha in very early onset inflammatory bowel disease. Inflamm Bowel Dis. Published online October 17, 2023. doi:10.1093/ibd/izad196 - DOI - PMC - PubMed
    1. Koudsi M, Martinez-Vinson C, Pigneur B, et al.Ustekinumab use in pediatric inflammatory bowel disease: a French multicenter study from the pediatric GETAID. J Pediatr Gastroenterol Nutr. 2023;76(6):763-770. - PubMed
    1. Rosh JR, Turner D, Griffiths A, et al.Ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: pharmacokinetics, safety, and efficacy results from UniStar, a phase 1 study. J Crohns Colitis. 2021;15(11):1931-1942. - PMC - PubMed
    1. Kim FS, Patel PV, Stekol E, et al.Experience using ustekinumab in pediatric patients with medically refractory Crohn Disease. J Pediatr Gastroenterol Nutr. 2021;73(5):610-614. - PMC - PubMed

Publication types